FilingReader Intelligence
Fosun Pharma subsidiary gets drug application accepted
July 11, 2025 at 09:41 AM UTC•By FilingReader AI
Shanghai Zhaohui Pharmaceutical Company, a Fosun Pharma subsidiary, announced its drug registration application for Polyethylene Glycol Electrolytes Powder (II) was accepted by the National Medical Products Administration. This chemical drug is for bowel cleansing.
The drug generated sales of approximately RMB307 million in China in 2024, with the group investing RMB4.74 million in research and development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2196•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical (Group) Co publishes news
Free account required • Unsubscribe anytime